Your browser doesn't support javascript.
loading
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong, Wen-Zhao; Wang, Qun; Mao, Wei-Min; Xu, Song-Tao; Wu, Lin; Shen, Yi; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Xu, Lin; Wang, Jun; Fei, Ke; Li, Xiao-Fei; Li, Jian; Huang, Cheng; Liu, Zhi-Dong; Xu, Shun; Chen, Ke-Neng; Xu, Shi-Dong; Liu, Lun-Xu; Yu, Ping; Wang, Bu-Hai; Ma, Hai-Tao; Yan, Hong-Hong; Yang, Xue-Ning; Zhou, Qing; Wu, Yi-Long.
Affiliation
  • Zhong WZ; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Wang Q; Fudan University Affiliated Zhongshan Hospital, Shanghai, China.
  • Mao WM; Zhejiang Cancer Hospital, Hangzhou, China.
  • Xu ST; Fudan University Affiliated Zhongshan Hospital, Shanghai, China.
  • Wu L; Hunan Cancer Hospital, Changsha, China.
  • Shen Y; The Affiliated Hospital of Medical College Qingdao University, Qingdao, China.
  • Liu YY; Liaoning Cancer Hospital, Shenyang, China.
  • Chen C; Fujian Medical University Union Hospital, Fuzhou, China.
  • Cheng Y; Jilin Provincial Tumor Hospital, Changchun, China.
  • Xu L; Jiangsu Cancer Hospital, Nanjing, China.
  • Wang J; The People's Hospital of Peking University, Beijing, China.
  • Fei K; Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
  • Li XF; Tangdu Hospital, Xi'an, China.
  • Li J; Peking University First Hospital, Beijing, China.
  • Huang C; Fujian Cancer Hospital, Fuzhou, China.
  • Liu ZD; Beijing Chest Hospital, Beijing, China.
  • Xu S; The First Hospital of China Medical University, Shenyang, China.
  • Chen KN; Beijing Cancer Hospital, Beijing, China.
  • Xu SD; Harbin Medical University Cancer Hospital, Harbin, China.
  • Liu LX; West China Hospital of Sichuan University, Chengdu, China.
  • Yu P; Sichuan Cancer Hospital, Chengdu, China.
  • Wang BH; The Northern Jiangsu People's Hospital, Yangzhou, China.
  • Ma HT; The First Affiliated Hospital of Suzhou University, Suzhou, China.
  • Yan HH; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Yang XN; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Zhou Q; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Wu YL; Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address: syylwu@live.cn.
Lancet Oncol ; 19(1): 139-148, 2018 01.
Article in En | MEDLINE | ID: mdl-29174310
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Vinblastine / Antineoplastic Combined Chemotherapy Protocols / Biomarkers, Tumor / Cisplatin / Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / ErbB Receptors / Lung Neoplasms / Mutation Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Aspects: Patient_preference Country/Region as subject: Asia Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2018 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Vinblastine / Antineoplastic Combined Chemotherapy Protocols / Biomarkers, Tumor / Cisplatin / Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / ErbB Receptors / Lung Neoplasms / Mutation Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Aspects: Patient_preference Country/Region as subject: Asia Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2018 Document type: Article Affiliation country: